- Home
- DOUG vs GLSI Comparison
DOUG vs GLSI Comparison
Compare DOUG & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- GLSI
- Stock Information
- Founded
- DOUG 1911
- GLSI 2006
- Country
- DOUG United States
- GLSI United States
- Employees
- DOUG N/A
- GLSI N/A
- Industry
- DOUG Building operators
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- GLSI Health Care
- Exchange
- DOUG Nasdaq
- GLSI Nasdaq
- Market Cap
- DOUG 142.2M
- GLSI 143.4M
- IPO Year
- DOUG N/A
- GLSI 2020
- Fundamental
- Price
- DOUG $1.79
- GLSI $12.87
- Analyst Decision
- DOUG
- GLSI Strong Buy
- Analyst Count
- DOUG 0
- GLSI 1
- Target Price
- DOUG N/A
- GLSI $38.00
- AVG Volume (30 Days)
- DOUG 1.0M
- GLSI 43.0K
- Earning Date
- DOUG 02-27-2025
- GLSI 11-14-2024
- Dividend Yield
- DOUG N/A
- GLSI N/A
- EPS Growth
- DOUG N/A
- GLSI N/A
- EPS
- DOUG N/A
- GLSI N/A
- Revenue
- DOUG $966,442,000.00
- GLSI N/A
- Revenue This Year
- DOUG $5.28
- GLSI N/A
- Revenue Next Year
- DOUG $16.40
- GLSI N/A
- P/E Ratio
- DOUG N/A
- GLSI N/A
- Revenue Growth
- DOUG 1.86
- GLSI N/A
- 52 Week Low
- DOUG $1.00
- GLSI $8.00
- 52 Week High
- DOUG $2.98
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- DOUG 51.94
- GLSI 51.89
- Support Level
- DOUG $1.49
- GLSI $11.50
- Resistance Level
- DOUG $1.84
- GLSI $12.84
- Average True Range (ATR)
- DOUG 0.12
- GLSI 0.90
- MACD
- DOUG 0.04
- GLSI 0.09
- Stochastic Oscillator
- DOUG 75.95
- GLSI 59.49
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.